4.7 Article

Effects of urea pretreatment on the binding properties of adenosine A1 receptors

期刊

BRITISH JOURNAL OF PHARMACOLOGY
卷 146, 期 8, 页码 1119-1129

出版社

WILEY
DOI: 10.1038/sj.bjp.0706419

关键词

adenosine; A(1) receptor; drug discovery; G protein-coupled receptor; kinetics; radioligand binding; urea

向作者/读者索取更多资源

1 The effect of denaturation and/or extraction of nonintegral membrane proteins by 7M urea on the binding of the antagonist [H-3] cyclopentyl-1,3-dipropylxanthine 8 dipropyl-2,3 ([ 3H] DPCPX), and the agonists adenosine, (-)-N-6-(2-phenylisopropyl)- adenosine (R-PIA) and N-6-cyclohexyladenosine (CHA), was investigated at human A(1) adenosine receptors stably expressed in CHO cells. 2 Pretreatment with urea caused a 56% reduction in membrane proteins. Compared to controls, the use of adenosine deaminase (ADA), 100 mu M 50-guanylylimidodiphosphate (Gpp(NH) p) or urea each caused equivalent increases in specific [H-3] DPCPX binding. 3 Neither the binding kinetics nor the affinity of [3H] DPCPX were significantly different in urea-pretreated compared to ADA-pretreated membranes. 4 At 25 degrees C in ADA-pretreated membranes, the competition isotherms for R- PIA and CHA were characterized by two affinity states. Gpp(NH) p ( 100 mM) reduced, but did not abolish, the value of the high-affinity dissociation constant. Similar results were obtained after treatment with urea for R- PIA, whereas the high-affinity state for CHA was abolished. 5 At 37 degrees C, urea pretreatment, but not 100 mu M Gpp(NH)p, abolished high-affinity agonist competition binding. There was no significant effect of any of the treatments on the low-affinity agonist binding state. 6 In urea-pretreated membranes, exogenously added adenosine competed according to a simple mass-action model with a pK(L) of 5.66 +/- 0.05 (n = 3). 7 Compared to the more common approaches of ADA treatment and/or use of guanine nucleotides, our findings suggest that urea pretreatment represents an inexpensive and useful approach for investigating the binding properties of adenosine A(1) ligands (including adenosine) to the G protein-uncoupled form of the receptor.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Pharmacology & Pharmacy

Structure-activity relationship of pyrazol-4-yl- pyridine derivatives and identification of a radiofluorinated probe for imaging the muscarinic acetylcholine receptor M4

Ahmed Haider, Xiaoyun Deng, Olivia Mastromihalis, Stefanie K. Pfister, Troels E. Jeppesen, Zhiwei Xiao, Vi Pham, Shaofa Sun, Jian Rong, Chunyu Zhao, Jiahui Chen, Yinlong Li, Theresa R. Connors, April T. Davenport, James B. Daunais, Vahid Hosseini, Wenqing Ran, Arthur Christopoulos, Lu Wang, Celine Valant, Steven H. Liang

Summary: This study aimed to develop a suitable M4 PET ligand for the non-invasive visualization of M4 in the brain. The compound 12 was identified as a subtype-selective positive allosteric modulator (PAM) and its radiofluorinated analogue showed moderate specificity in rodent brain sections. However, in non-human primates and humans, the presence of carbachol did not improve the specificity and selectivity of the radioligand.

ACTA PHARMACEUTICA SINICA B (2023)

Article Pharmacology & Pharmacy

Importance of receptor expression in the classification of novel ligands at the M2 muscarinic acetylcholine receptor

Ye Jiang, Mahmuda Yeasmin, Arisbel B. Gondin, Arthur Christopoulos, Celine Valant, Wessel A. C. Burger, David M. Thal

Summary: This study investigated the activation of individual G protein subfamilies and downstream signaling pathways of compounds 6A and 7A at the M-2 mAChR. The results showed that M-2 mAChR primarily couples to Galpha(i/o) and Galpha(s), but no Galpha(i) bias was detected for compounds 6A and 7A. This highlights the importance of cellular background in classifying new ligands.

BRITISH JOURNAL OF PHARMACOLOGY (2023)

Review Pharmacology & Pharmacy

Therapeutic potential of allosteric modulators for the treatment of gastrointestinal motility disorders

Ayame Saito, Sadia Alvi, Celine Valant, Arthur Christopoulos, Simona E. Carbone, Daniel P. Poole

Summary: The enteric nervous system plays a crucial role in regulating gastrointestinal motility. Disrupted enteric nervous system activity can lead to dysmotility. Pharmacological treatment options for dysmotility involve targeting G protein-coupled receptors (GPCRs) expressed by enteric nervous system neurons. Current drugs that target GPCRs for motility disorders have drawbacks such as significant side-effects and a loss of physiological tone. Allosteric modulation of GPCRs, which bind to a distinct site from the endogenous ligand, may provide effective relief from motility disorders while minimizing side-effects.

BRITISH JOURNAL OF PHARMACOLOGY (2023)

Review Endocrinology & Metabolism

New Insights into the Structure and Function of Class B1 GPCRs

Brian P. Cary, Xin Zhang, Jianjun Cao, Rachel M. Johnson, Sarah J. Piper, Elliot J. Gerrard, Denise Wootten, Patrick M. Sexton

Summary: G protein-coupled receptors (GPCRs), particularly the B1 class, play a critical role in maintaining homeostasis and are important drug targets. Recent advances in cryo-electron microscopy have provided valuable insights into the structure and dynamics of these receptors, which contribute to our understanding of their functions.

ENDOCRINE REVIEWS (2023)

Review Pharmacology & Pharmacy

The application of artificial intelligence to accelerate G protein-coupled receptor drug discovery

Anh T. N. Nguyen, Diep T. N. Nguyen, Huan Yee Koh, Jason Toskov, William MacLean, Andrew Xu, Daokun Zhang, Geoffrey I. Webb, Lauren T. May, Michelle L. Halls

Summary: The application of artificial intelligence in drug discovery for G protein-coupled receptors (GPCRs) is expanding rapidly. It can assist in understanding the actions of GPCRs, discovering new ligand-GPCR interactions, and predicting clinical responses. This article provides an overview of artificial intelligence concepts and its applications in different stages of GPCR drug discovery. The benefits and limitations of artificial intelligence are discussed, along with the potential for further development in assisting GPCR drug discovery.

BRITISH JOURNAL OF PHARMACOLOGY (2023)

Review Pharmacology & Pharmacy

The role of the adenosine system in epilepsy and its comorbidities

Jo-Anne Baltos, Pablo M. Casillas-Espinosa, Ben Rollo, Karen J. Gregory, Paul J. White, Arthur Christopoulos, Patrick Kwan, Terence J. O'Brien, Lauren T. May

Summary: Epilepsy, a serious neurological condition, affects millions of people worldwide. Current pharmacotherapy only successfully controls seizures in about 70% of epilepsy patients, and many suffer from psychiatric and physical comorbidities. Adenosine, a natural substance, has shown potential as an anti-epileptic agent through its receptor activation. Recent advances have also shown that adenosine receptors can modulate epilepsy-associated comorbidities. This review provides an accessible resource on the use of the adenosine system as a therapeutic target for epilepsy and its associated comorbidities.

BRITISH JOURNAL OF PHARMACOLOGY (2023)

Review Pharmacology & Pharmacy

Targeting G protein-coupled receptors for heart failure treatment

Bui San Thai, Ling Yeong Chia, Anh T. N. Nguyen, Chengxue Qin, Rebecca H. Ritchie, Dana S. Hutchinson, Andrew Kompa, Paul J. White, Lauren T. May

Summary: Heart failure remains a significant cause of morbidity and mortality worldwide. Current treatment options have limitations, leading to many patients progressing to advanced stages. Exploration of novel therapeutics targeting G protein-coupled receptors (GPCRs) has shown promise, but efficacy and unwanted effects remain as challenges.

BRITISH JOURNAL OF PHARMACOLOGY (2023)

Correction Biochemistry & Molecular Biology

Structural basis of efficacy-driven ligand selectivity at GPCRs (Feb, 10.1038/s41589-022-01247-5, 2023)

Alexander S. Powers, Vi Pham, Wessel A. C. Burger, Geoff Thompson, Yianni Laloudakis, Nicholas W. Barnes, Patrick M. Sexton, Steven M. Paul, Arthur Christopoulos, David M. Thal, Christian C. Felder, Celine Valant, Ron O. Dror

NATURE CHEMICAL BIOLOGY (2023)

Article Biochemistry & Molecular Biology

Structural basis of efficacy-driven ligand selectivity at GPCRs

Alexander S. Powers, Vi Pham, Wessel A. C. Burger, Geoff Thompson, Yianni Laloudakis, Patrick M. Sexton, Steven M. Paul, Arthur Christopoulos, David M. Thal, Christian C. Felder, Celine Valant, Ron O. Dror

Summary: The selectivity of a drug for target receptors is crucial but challenging when the receptors are similar. Serendipitous discovery of ligands that stimulate target receptors more strongly than closely related receptors provides a solution. This study reveals the structural basis for the efficacy-driven selectivity of xanomeline, a clinical drug candidate, between closely related muscarinic acetylcholine receptors (mAChRs), using atomic-level simulations. The results suggest strategies for rational design of ligands achieving efficacy-driven selectivity for G-protein-coupled receptors.

NATURE CHEMICAL BIOLOGY (2023)

Article Multidisciplinary Sciences

Xanomeline displays concomitant orthosteric and allosteric binding modes at the M4 mAChR

Wessel A. C. Burger, Vi Pham, Ziva Vuckovic, Alexander S. Powers, Jesse I. Mobbs, Yianni Laloudakis, Alisa Glukhova, Denise Wootten, Andrew B. Tobin, Patrick M. Sexton, Steven M. Paul, Christian C. Felder, Radostin Danev, Ron O. Dror, Arthur Christopoulos, Celine Valant, David M. Thal

Summary: The M4 muscarinic acetylcholine receptor is a significant drug target for the treatment of psychosis, cognition, and addiction. The clinical trial of xanomeline has shown promise in improving symptoms and the cryo-EM structure reveals the binding mechanism, providing insight into its complex pharmacology.

NATURE COMMUNICATIONS (2023)

Meeting Abstract Pharmacology & Pharmacy

Bias profile and efficacy-driven selectivity of xanomeline at the muscarinic acetylcholine receptor family

Celine Valant, Alexander Powers, Vi Pham, Wessel Burger, Emma van der Westhuizen, Nicholas Barnes, Steven Paul, Arthur Christopoulos, David Thal, Christian Felder, Ron Dror

BRITISH JOURNAL OF PHARMACOLOGY (2023)

Meeting Abstract Pharmacology & Pharmacy

Low allosteric agonism and moderate modulation are required for optimal therapeutic window for positive allosteric modulators of the M1 muscarinic acetylcholine receptor

Huong Thi Mai Nguyen, Emma van der Westhuizen, Elham Khajehali, Arthur Christopoulos, Celine Valant

BRITISH JOURNAL OF PHARMACOLOGY (2023)

暂无数据